Add-on NE3107, now bezisterim, eases Park... - Cure Parkinson's
Add-on NE3107, now bezisterim, eases Parkinson’s symptoms
"The Phase 2a study included 46 adults with Parkinson’s, ages 30 to 80, who were randomly assigned to either 20 mg bezisterim or a placebo, taken as capsules by mouth twice daily for 28 days, on top of their standard carbidopa/levodopa medication.
Bezisterim resulted in a 2.8-point greater reduction on part 3 of the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), a measure of how severe motor symptoms are, compared with a placebo. In the MDS-UPDRS, lower scores mean less severe symptoms.
In line with a previous analysis of the data, patients younger than 70, who made up about half of the study population, showed an even greater difference in motor symptoms, an advantage of 4.7 points in favor of bezisterim."
2.8-point reduction, average. Younger than 70, about half of the study, 4.7 points => .9 points for older than 70